The mechanism(s) by which acute promyelocytic leukemia (APL) cells acquire resistance to all-trans retinoic acid (ATRA) is poorly understood. We describe here an APL cell line, named NB4.306, that shows resistance to the antiproliferative action of ATRA. This cell line is also operationally resistant to most ATRA-induced phenotypic modifications (CDI 1 b, CDI 1 c, CDI 3, and CD33). No significant differences in ATRA intracellular accumulation, efflux, or metabolism were found between NB4.306 and the parent NB4 cell line that could explain the obsetved resistance of the NB4.306 line. The NB4.306 cell line was found to be positive for the t l 5 ; 17 translocation and showed the usual
The mechanism(s) by which acute promyelocytic leukemia (APL) cells acquire resistance to all-trans retinoic acid (ATRA) is poorly understood. We describe here an APL cell line, named NB4.306, that shows resistance to the antiproliferative action of ATRA. This cell line is also operationally resistant to most ATRA-induced phenotypic modifications (CDI 1 b, CDI 1 c, CDI 3, and CD33). No significant differences in ATRA intracellular accumulation, efflux, or metabolism were found between NB4.306 and the parent NB4 cell line that could explain the obsetved resistance of the NB4.306 line. The NB4.306 cell line was found to be positive for the t l 5 ; 17 translocation and showed the usual
CUTE PROMYELOCYTIC leukemia (APL) accounts
A for 5% to 10% of all acute myelogenous leukemia (AML) cases. An important and distinguishing feature of the APL phenotype is the in vitro and in vivo high sensitivity of the leukemic blasts to the differentiative action of retinoic acid (RA), in particular to all-trans RA (ATRA).',' Although ATRA can induce disease remission in most APL patients, responses are usually short-lived.' APL is also distinguished from other AML subtypes by the presence of a reciprocal chromosome 15;17 transl~cation.~ The chromosome breakpoints lie within the PML gene on 15 and within the retinoic acid receptor a (RARa) gene on 17.& RARa is one of the intracellular receptors that function to regulate gene expression in response to the binding of RA,' and there is evidence that it is involved in the control of RA-induced terminal myeloid differentiation.' A pml/RARa chimeric gene encoding a fusion pml/RARa protein is formed as a result of the translocation?" There is preliminary evidence that, paradoxically, the pml/RARa protein may contribute both to the differentiation block of the leukemic phenotype and to the unique sensitivity of APL blasts to the differentiating action of RA." We describe here the generation of an APL cell line resistant to RA, derived from the NB4 line,I2 and show that it lost expression of the intact pml/RARa protein.
MATERIALS AND METHODS
ATRA. ATRA (Sigma, St Louis, MO) was resuspended in ethanol at lo-' mol/L and stored at -20 C in the dark. A new solution was prepared every 2 weeks.
Cell lines. The NB4 APL cell line'* was kindly provided by Dr M. Lanotte (Paris, France) and grown in RPMI 1640 plus 10% fetal calf serum (FCS) (complete medium [CM] ). The cells were mutagenized with low-dose radiation (300 cGy), cultured for 14 days in CM, and then resuspended in CM plus ATRA mol/L. The concentration of ATRA was subsequently increased to mol/L (see Results).
Indirect immunofluorescence. This assay was performed as previously described.I3 Samples were incubated with 1/100 rabbit serum at room temperature for 10 minutes before the primary antibody was added. Mouse serum was used as negative control. and II), 3 .9 (anti-CDIlb and CDllc), U71 and CH153 (anti-CDI3 and CD33). Samples were analyzed by flow cytometry (FACS IV, Becton Dickinson, Sunnyvale, CA) using a logarithmic signal amplification.
Accumulation and eflux ofATRA. To measure drug accumulation, cells (lo7 in 4 mL CM) were incubated with ATRA mol/L) at 37°C for 30,60, 120, and 180 minutes. To measure drug efflux, cells were incubated with ATRA for 60 minutes, washed twice in ice-cold phosphate-buffered saline (PBS), and further incubated in drug-free medium for 15, 30,60, and 120 minutes. At the selected time, 6 mL of ice-cold PBS was added to stop drug uptake and efflux. Cells were centrifuged and washed with additional icecold PBS. The cell pellets were rapidly frozen in liquid nitrogen. After thawing, the cell pellets were suspended in 1 mL of water containing butylated hydroxytoluene (Sigma, 370 pg/mL) as antioxidant. All of the procedures were performed with the samples protected from light. ATRA concentrations (nanograms per IO7 cells) were determined by high-performance liquid chromatography (HPLC) as previously de~cribed.'~ The reading was performed at 345 nm. A peak coeluting with 13-cis RA (Sigma), used as reference standard, was also evidenced. Within each experiment, determinations were performed in triplicate.
Proliferative activity. Cells (10' per well) were cultured in the presence or absence of 1 0-6 mol/L ATRA for 7 days, incubated for an additional 6 hours with 'H-thymidine ('HTdR; 1 pCi per well), and harvested. Values are expressed as counts per minute (cpm) and represent the mean of six replicates.
DNA extraction and Southern blot analysis. Cellular DNA extraction and Southern blot analysis were performed according to established proced~res.'~ Samples were digested with Hind111 and the RH15 probe'' was used for hybridization.
RNA extraction and Northern blot analysis. Total RNA was prepared according to the guanidine-isothiocyanate method. Twenty micrograms of total RNA was separated on a 1.2% agaroseformaldehyde gel and transferred to a nitro cellulose filter. Filters were hybridized with the RARa probe IT. 16 Protein extraction and Western blot analysis. NB4 and NB4.306 cells (3 X IO6) were resuspended at 0°C in 50pL ofsuspension buffer containing 0. I mol/L NaC1, 10 mmol/L Tris-HC1 (pH 7.6), 1 mmol/L EDTA (pH 8.0), I pglmL aprotinin, 100 pg/ml Phenylmethylsulfonyl fluoride. The cells were lysed by adding 50 p L of lysis buffer containing 100 mmol/L Tris-HC1 (pH 6 4 , 200 mmol/L dithiotreitol, 4% sodium dodecyl sulfate (SDS), 0.2% bromophenol blue, and 20% glycerol (all from Sigma). Samples were then boiled for I O minutes, sonicated, and centrifuged. Aliquots of the supernatants were fractionated by electrophoresis on 10% SDS acrylamide gel and electrotransferred to nitrocellulose sheets, blocked with 3% nonfat powdered milk in PBS, and then incubated for 2 hours at 37°C with a rabbit polyclonal antibody against the RARa F domain (RPa[F], a gift from Dr P. Chambon, Strasbourg, France)." After extensive washing, the blots were incubated for 90 minutes with radioiodinated protein A at 25"C, dried, and audioradiographed.
RA-binding assay. Nuclear extracts, labeling with 'H-RA, and HPLC analysis were performed as previously described.'*
RESULTS
Generation of an ATRA-resistant APL cell line. The NB4 cell line was mutagenized to increase the rate of mutations and then cultured in the presence of ATRA, initially at IO-' mol/L. After an initial IO-fold decrease in cell number, the culture remained stable in number for 1 month and then began to grow. The concentration of ATRA was increased to mol/L. An additional 6 weeks were needed to obtain constant growth at this concentration. After 3 months of additional culture, the resulting cell line was named NB4.306. The NB4.306 cell line is morphologically similar to the parent NB4 line and is cultured in CM plus mol/L ATRA. Figure 1 shows the effect of ATRA on the growth of NB4 and NB4.306, as measured by cell counts (Fig IA) and 3HTdR uptake (Fig IB) . The NB4 cell line showed the usual decline in number, when cultured in the presence of ATRA. The NB4.306 line instead was unaffected by ATRA and grew similarly to the NB4 line cultured in the absence of ATRA, with a doubling time of approximately 48 hours. The growth of the NB4.306 cell line was unaffected by ATRA concentrations up to mol/L (data not shown). The 'HTdR uptake values (Fig 1B) confirmed these findings. The NB4 line cultured in ATRA showed an eightfold decrease in the counts-per-minute values in comparison to control NB4; the NB4.306 cells were instead unaffected by the presence of ATRA. The culture of NB4.306 in ATRA-free CM for 6 days before the experiment produced similar results.
Phenotype of the NB4.306 cell line. The NB4.306 and NB4 cell lines were analyzed for the expression of various markers, both in presence and in absence of ATRA. HLA class I molecules are constitutively expressed in APL, while HLA class I1 (DR) molecules are constantly negative. CD1 I b and CD1 IC are adhesion molecules whose expression increases during granulocytic differentiation and can be induced by ATRA in NB4 cells." CD13 and CD33 are myeloid markers that are downregulated in response to ATRA. The results are presented in Table 1 . Both lines are positive for HLA class I expression and negative for DR Accumulation and eflux of ATRA in NB4 and NB4.306 cell lines. To investigate whether ATRA resistance could be due to a reduced uptake of ATRA by the NB4.306 cell line, the intracellular content of the drug was determined in two separate experiments after incubating the cells with 1 0-6 mol/L ATRA. Steady-state concentrations of ATRA were achieved by 30 to 60 minutes in both the NB4 and NB4.306 cell lines. There was no significant difference between the sensitive and the resistant cell line in the levels of drug accumulation. At the 60-minute time point, NB4 and NB4.306 cells contained 13 1.5 f 33 (SD) and 168.4 f 37 ng ATRAI10' cells, respectively (P > .OS as determined by one-way variance analysis). These results did not change if the values were expressed as nanograms of ATRA per milligram cellular protein. The efflux of ATRA from the cells following the removal of ATRA from the medium was also rapid, with 94% (NB4) and 87% (NB4.306) ofthe drug being eliminated from the cells after 15 minutes (P > .OS). The intracellular content of a compound that coeluted with 13-cis RA, an ATRA metabolite, ranged at the different time points between 8% and 38% in the two experiments, with no significant difference between the two lines, suggesting metabolism of ATRA or spontaneous isomerization. These data failed to show major differences in the cellular pharmacokinetics of ATRA that could be responsible for the observed resistance of the NB4.306 cell line.
Genetic and molecular analysis of the NB4.306 cell line. Cytogenetic analysis of the NB4.306 cell line showed the presence of a hypotriploid karyotype with a variable number (modal number 64) of chromosomes, and the presence ofthe same marker chromosomes observed in the NB4 cell line, including two copies of the t(15;17) (data not shown). Thus, the lowdose radiation treatment does not seem to have induced major chromosomal abnormalities in comparison with the parental line.
Southern blot analysis using the RH I5 pml DNA probe showed the presence of similarly sized rearranged fragments corresponding to the pml/RARa fusion gene in both NB4 and NB4.306 samples (Fig 2A) . Northern blot analysis using the RARa IT probe showed apparently identical RARa and pml/RARa transcripts in both the parental NB4 and in the ATRA-resistant NB4.306 cell lines (Fig 2B) . Finally, Western blot analysis of total proteins using the RPa(F) anti-RARa antibody confirmed the presence of an approximately 1 1 0-Kd immunoreactive polypeptide corresponding to the pml/RARa protein in the NB4 cell line. The same polypeptide was not detected in the NB4.306 cell line ( Fig  2C) . Note that the approximately 50-Kd polypeptides corresponding to the wild-type RARa protein migrated with apparently identical molecular weights in the NB4 and NB4.306 cell lines. Similarly, no expression of the pml/ RARa fusion protein was detected by Western blotting in 14 of 14 subclones obtained from the NB4.306 cell line, while 30 of 30 clones obtained from the parental NB4 cell line maintained sensitivity to ATRA and continued to express the usual pml/RARa protein (data not shown).
RA-binding activity. Nuclear extracts from the NB4.306 and NB4 cell lines were assayed for RA-binding activity." Two peaks of specific RA binding corresponding to molecular weights (MWs) of approximately 50 and 110 Kd were observed in the NB4 extract; two additional peaks corresponding to MWs of 460 and 600 Kd were noted, compatible with the formation of high-MW complexes between pml/RARa and itself or other nuclear proteins, as previously reported." Only the 50-Kd peak was present in the NB4.306 extract (data not shown).
These data indicate that the NB4.306 mutant cell line retained the pml/RARa fusion gene and that, although transcriptionally active, it lost the potential to encode for an intact, RA-binding pml/RARa fusion protein.
DISCUSSION
Major features of APL cells include the block of differentiation ofthe leukemic blasts and their high sensitivity to the differentiative action of RA. Circumstantial evidence suggests that the pml/RARa protein contributes to the transformed phenotype by interfering with the differentiation program of target promyelocytes and also contributes to the response of APL blasts to RA. The pml/RARa fusion protein is also specifically recognized by human T lymphoc y t e~'~ and could become the target for specific immunotherapy. The availability of APL cell lines with absent/altered expression of the pml/RARcr protein would be of interest to dissect the biologic activity and the immunogenicity ofthe pml/RARa protein better, as well as to investigate the phenomenon of RA resistance in APL. We reasoned that, being pml/RARa-positive cells highly sensitive to ATRA, cell lines resistant to RA and not expressing the pml/RARa fusion protein could be obtained by culturing APL cells in ATRA.
We report the isolation of an APL cell line mutant, which, with respect to the parental cell line, concomitantly lost RA sensitivity and the expression of the intact pml/RARa protein. This alteration is not due to the occurrence of gross abnormalities of the pml/RARa gene, as shown by the presence of apparently normally sized pml/RARa DNA fragments and transcript. Several cell lines obtained after the establishment of line NB4.306, as well as all the clones obtained from these lines, show the Same loss of expression of the intact pml/RARa protein. These results establish a strict correlation between pml/RARa expression and RA sensitivity in APL and suggest that pml/RARa is involved in the response to RA in APL, and may be a target for mutations that confer resistance to RA of APL blasts. Therefore, the expression of an intact pml/RARa protein could be necessary for the high sensitivity of APL cells to ATRA. These findings are at difference with previous models of RA resistance obtained in cells of different origin and not expressing the pml/RARa fusion Recently, Duprez et al described a variant of the NB4 cell line that has been maintained in culture conditions similar but not identical to ours and shows a similar resistance to ATRA.23 However, the investigators did not present data on the expression of the pml/RARa protein and concluded that "the molecular basis for unresponsiveness to RA is not known." Intracellular pharmacokinetic experiments indicate that differences in ATRA accumulation or efflux do not seem to be implicated in the resistance of NB4.306 cells to RA.
The mechanism(s) by which the absent/altered pml/ RARa molecule generates the observed resistance to ATRA is unknown. It is possible that a truncated pml/RARa protein could still be produced and could form heterodimers with the normal RARa protein, thereby inhibiting its activity. The weak ATRA-induced phenotypic changes observed in the NB4.306 line support such a hypothesis. The lack ofa RA-binding activity attributable to the pml/RARa protein is consistent with the absence of this molecule or with the synthesis of an abnormal molecule that is unable to bind RA, but could still inhibit the normal RARa protein.
Whether the mutagenization protocol we used induced additional abnormalities that could promote independent growth is not known. However, in this context, it is worth mentioning that additional NBbderived, ATRA-resistant APL lines were generated in our laboratory without previous radiation. These lines do not express the intact pml/ RARa protein, similarly to NB4.306 (data not shown). The culture in the presence of ATRA seems instead necessary for the growth of resistant lines, since many clones derived from NB4 without ATRA continued to show ATRA sensitivity and expression of the pml/RARa protein. These findings indicate that ATRA-resistant cells were induced during the culture in ATRA or that they were present in the NB4 line at a very low frequency.
It remains to be established whether the pml/RARa protein is absent in NB4.306 cells or whether an aberrant truncated protein, lacking the domain recognized by the antiRARa antibody used, is still produced. In particular, it is not known whether the fusion region is translated. This is of particular importance for the investigation of the specific immune recognition of this molecule in the NB4.306 cell line." In any case, our results indicate that in APL cells the loss of sensitivity to ATRA is closely associated with an alteration in the expression of the APL-specific pml/RARa molecule.
The presence of a tumor-specific/transformation-related molecule in APL represents the molecular basis for a tumorselective treatment of this disease. This information can potentially be used to produce different treatment modalities, including the pharmacologic manipulation of the hybrid protein using RA,24 the specific immune recognition of the pml/RARa protein by T lymphocytes," or the targeting of the pml/RARa mRNA using anti-sense oligonucleotides. The sequencing of the pml/RARa mRNA from NB4.306 cells will elucidate the molecular mechanism(s) leading to the observed lack of expression of the intact pml/RARa protein, and could potentially be used to detect the presence or the emergence of RA-resistant APL cells.25
These data also suggest that when a specific anticancer treatment is available, the occurrence of additional genetic damage, both spontaneous or treatment-induced, could even antagonize the specific treatment by rendering the growth of the neoplastic cells independent from the targeted oncogenic protein(s).
